Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 19/20 | 0.71 |
| ▸ | MMP1 | P03956 | 1/20 | 0.71 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201043 | 0.90 | ADAMTS5 (0.57) | ADAMTS5MMP1ADAM17MMP2MMP13 | |
| SCHEMBL23901340 | 0.89 | ADAMTS5 (0.73) | ADAMTS5MMP1ADAM17MMP2MMP13 | |
| SCHEMBL22201051 | 0.89 | ADAMTS5 (0.73) | ADAMTS5MMP1ADAM17MMP2 | |
| SCHEMBL19996698 | 0.85 | ADAMTS5 (0.69) | ADAMTS5MMP1ADAM17MMP2AR | |
| SCHEMBL17871126 | 0.83 | ADAMTS5 (1.00) | ADAMTS5MMP1ADAM17MMP2MMP13 | |
| SCHEMBL17871116 | 0.83 | ADAMTS5 (1.00) | ADAMTS5MMP1ADAM17MMP2MMP13 | |
| SCHEMBL23901338 | 0.82 | ADAMTS5 (0.71) | ADAMTS5ADAM17MMP2MMP13 | |
| SCHEMBL25948021 | 0.81 | ADAMTS5 (0.72) | ADAMTS5MMP1ADAM17AR | |
| SCHEMBL22201090 | 0.78 | ADAMTS5 (0.67) | ADAMTS5MMP1ADAM17MMP2AR | |
| SCHEMBL23901276 | 0.78 | ADAMTS5 (0.75) | ADAMTS5ADAM17MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | ADAMTS5 2/4885MMP1 10/4885ADAM17 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.